Concomitant Hybrid Versus Catheter Ablation for Atrial Fibrillation With Hypertrophic Cardiomyopathy
Concomitant Hybrid Versus Catheter Ablation for Reinforcing Therapeutic Effect of Atrial Fibrillation With Hypertrophic Cardiomyopathy
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Contact
Study Contact
- Name: Zhe Zheng, MD.PhD
- Phone Number: +86-010-88396051
- Email: zhengzhe@fuwai.com
Study Contact Backup
- Name: Yajie Tang, MD.PhD
- Phone Number: +8618813019554
- Email: tangyajietangyajie@126.com
Study Locations
-
-
-
Beijing, China
- Recruiting
- Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College
-
Contact:
- Yajie Tang, MD,PhD
- Phone Number: +8618813019554
- Email: tangyajietangyajie@126.com
-
Contact:
- Zhe Zheng, MD,PhD
- Phone Number: +86-010-88396051
- Email: zhengzhe@fuwai.com
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Patients' age is ≥18 y
- Clinically diagnosed hypertrophic cardiomyopathy (any left ventricular wall segment thickness ≥15 mm in genetical negative (or unknown genetical status) patients or ≥13mm in genetical positive ones-as measured by any imaging technique (echocardiography, cardiac magnetic resonance imaging or computed tomography)-that is not explained solely by loading conditions)
- Non-obstructed left ventricular outflow obstruction with peak gradients <30mmHg
- Concomitant with persistent atrial fibrillation (7 days<sustained episode lasting<3 years) with drug-refractory symptoms.
- Be able to understand the contents of the trial, and provide written informed consent to participate in this investigation.
Exclusion Criteria:
- Patients with left atrial size >60 mm (2-dimensional echocardiography, parasternal long-axis view)
- Contraindicated to systemic anticoagulation
- Left ventricular ejection fraction ≤40%
- Concomitant with left atrium or left atrial appendage emboli
- Concomitant with a coronary or valvular disease that indicates intervention
- Ischaemic stroke within 2 months
- Previous ablation history
- Uncontrolled hyper/hypothyroidism
- End-staged kidney failure
- Concomitantly involved in other trials
- Pregnant or breastfeeding, or women of childbearing age not using a reliable contraceptive method
- Concomitant with bacteremia or at an active phase of infection
- Anatomically not suitable for thoracoscopic surgery(history of chest surgery or radiotherapy, etc.)
- Unwilling or unable to comply with all peri-ablation and follow-up requirements
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: hybrid ablation
Participants in this group will receive concomitant thoracoscopic epicardial ablation and catheter endocardial ablation
|
simultaneous thoracoscopic epicardial and catheter endocardial ablation
|
|
Active Comparator: catheter ablation
Participants in this group will receive catheter endocardial ablation only
|
catheter endocardial ablation
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Freedom from documented recurrence (off-AADs)
Time Frame: within 3-12 months
|
freedom from documented AF/AT episodes >30 seconds (off-AADs) by 72-hour holter monitoring
|
within 3-12 months
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
All-cause rehospitalization
Time Frame: within 3-12 months
|
Rehospitalized by any reason
|
within 3-12 months
|
|
Heart failure related rehospitalization
Time Frame: within 3-12 months
|
Rehospitalized by the cause of heart failure episode
|
within 3-12 months
|
|
All cause mortality
Time Frame: within 12 months
|
death by any reason
|
within 12 months
|
|
Cardiovascular related mortality
Time Frame: within 12 months
|
death that related to cardiogenic causes
|
within 12 months
|
|
Cerebral infarction/ischemia
Time Frame: within 12 months
|
Any stroke or TIA diagnosed in the clinical record after the completion of the intervention
|
within 12 months
|
|
Periferal arterial embolism
Time Frame: within 12 months
|
Periferal arterial embolism
|
within 12 months
|
|
Freedom from documented recurrence (on-AADs)
Time Frame: within 3-12 months
|
freedom from documented AF/AT episodes >30 seconds (on-AADs) by 72-hour holter monitoring
|
within 3-12 months
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Study Chair: Zhe Zheng, MD.PhD, Chinese Academy of Medical Sciences, Fuwai Hospital
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- 2022-1736
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.